Thomas A. Greaney is no longer serves as Chief Operating Officer, Medical Devices of the Company effective 12/30/2020. In August 2017, Mr. Greaney was promoted to Chief Operating Officer, Medical Devices. Prior to joining Surmodics, he served as Chief Executive Officer for Creagh Medical, from September 2005 to November 2015. Prior to his tenure in Creagh Medical, Mr. Greaney served in a variety of roles with Boston Scientific for 10 years including the world-wide operations responsibility for the Taxus Stent commercialization. From 1989 to 1995, he worked for a number of Electronics companies in a variety of engineering and management roles.
As the Chief Operating Officer e Medical Devices of Surmodics, the total compensation of Thomas Greaney at Surmodics is $847,132. There are 5 executives at Surmodics getting paid more, with Gary Maharaj having the highest compensation of $2,343,630.
Thomas Greaney is 53, he's been the Chief Operating Officer e Medical Devices of Surmodics since 2017. There are 16 older and 4 younger executives at Surmodics. The oldest executive at Surmodics, Inc. is David Dantzker, 76, who is the Independent Director.
Thomas's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj e Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: